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Introduction
Head and neck cancers are among the most common in the world (5th leading cancer by incidence (Parkin et al., 2005) ). The American Joint Committee on Cancer (AJCC) staging is generally used to estimate the prognosis and guide therapy (Edge and Compton, 2010) . Radiochemotherapy is a standard treatment of unresectable and/or locally advanced Head and Neck Cancers (Pignon et al., 2000; St Guily et al., 2010) . Despite this treatment, the prognosis remains worst and loco-regional recurrence may occur in up to 40% patients, mostly within the first 2-years after treatment (Chajon et al., 2013) . positron emission tomography/computed tomography (PET/CT) allows to quantify the metabolic activity of a tumor (glycolysis) and has become a reference tool in oncology for the staging, radiotherapy planning and monitoring tumor response in many cancers (Cacicedo et al., 2016; Fletcher et al., 2008) . For primary tumor diagnosis, 18 F-FDG-PET imaging showed a significant better sensitivity (93% vs 65%) and specificity (70% vs 56%) over CT (Gambhir et al., 2001) . PET imaging allows a more accurate nodal staging of locally advanced head and neck cancer (Kyzas et al., 2008; Yoo et al., 2013) , and could result in changing the therapeutic management in nearly 15% of patients (Lonneux et al., 2010) . For patients with cervical node metastases of unknown primary, PET/CT detected a primary tumor in nearly 30% of patients (Rudmik et al., 2011; Wong et al., 2012; Zhu and Wang, 2013) .
Thanks to these potential advantages, PET/CT is recommended for the initial staging and for the treatment decision algorithm of advanced head and neck cancer (Yoo et al., 2013) .
However, in almost all of these studies, only a visual analysis of PET/CT by physician, based on contrast in uptake between normal tissues and potential tumor (i.e. operator dependent), was performed. Visual analysis was sufficient for diagnosis, staging and detection of recurrence, but with the goal of predicting patient' outcome, quantification is necessary. More recently, quantitative analyses have been introduced in order to overcome some of the limits of the visual methods (Table 1) . Indeed, quantitative analysis is less operator dependent than visual analysis and can be fully automated, allowing an easier and more objective comparison of the inter-and intra-patient variations. The main goal of the quantification is to obtain parameters reflecting the tumor activity and/or having a prognostic value.
The aims of this review were to report available evidences on the value of quantitative parameters from PET/CT performed at the diagnosis, during treatment and during follow to predict overall-and disease free survival in head and neck cancer and to discuss theirs limits.
Materials and methods
We performed a systematic electronic search of articles published in PubMed/MEDLINE from January 2000 to march 2016. Our search was restricted to articles reporting data obtained on humans and to English-written articles dealing with locally advanced head and neck cancer and PET/CT. All the articles which did not report data on the prognostic value of PET/CTrelated parameters were excluded as well as all the articles which reported data obtained only from visual analyses. Hence this review was focused on the prognostic value of parameters obtained from quantitative or semi-quantitative analyses. We included all the studies reporting data on PET/CT performed before, during or after exclusive RT +/-CT, excluding those reporting data from surgical series and/or post-operative radio-chemotherapy. The predictive value of PET at diagnosis, during treatment and during follow up was analyzed separately.
Results
One hundred and twenty-five studies were identified according to the criteria described above. Seventy-seven studies were excluded since they did not match the inclusion criteria, mainly because they dealt with operated patients (22/77 studies). One retrospective study presenting data on a small population (< 20 patients) was also excluded. Finally, 45 studies were included in the analysis, for a total of 2928 patients. Table 2 summarizes the main   characteristics of the studies included in this analysis, while table 3 summarizes the principal results of these studies.
Predictive value of 18FDG PET before treatment with RT-CT
Forty-two studies investigated the predictive value of quantitative PET parameters at diagnosis (Table 4) . The large majority of these studies analyzed parameters based on Standard Uptake Value (SUV), while only 3 studies performed texture or shape analysis.
SUVmax and Metabolic Tumor Volume
Maximum standard uptake value (SUVMax) corresponding to the maximal pixel value in the tumor. Thanks to its ease of use, it was historically the first parameter analyzed. SUVmax was correlated with overall-or disease free survival in 11 studies (Allal et al., 2002; Brun et al., 2002; Castaldi et al., 2012; Chen et al., 2014; Farrag et al., 2010; Higgins et al., 2012; Kitagawa et al., 2003; Machtay et al., 2009; Matoba et al., 2015; Rasmussen et al., 2015; Sanghera et al., 2005) . SUVmax allows to identify patients with a high risk of events (death or recurrence).
For example, (Rasmussen et al., 2015) analyzed 287 patients with locally advanced head and neck cancers treated with radiotherapy +/-chemotherapy. SUVmax showed a higher predictive value for recurrence than T stage, N stage and age. The authors developed a prognostic model of freedom from failure at 2 years, in which including SUVmax significantly increased the predictive value, changing the estimated risk by more than 10% for 23% of the patients. In (Allal et al., 2002) , 63 patients treated with RT +/-CT were prospectively included.
Patients presenting a SUVMax < 5.5 g/ml had a 3-year DFS of 79% compared to 42% for those with SUVmax > 5.5 g/ml (p=0.005). However, the range of cutoff values adopted in published studies to define patients at high or low risk of events markedly varied between 3.7 and 9 g/ml (median: 5.8). Noteworthy, also 2 negative studies are available in the literature (Ashamalla et al., 2014; Greven et al., 2001) . In (Greven et al., 2001) , patients with local recurrence had a mean pretreatment SUVMax of 7.7 g/ml versus 8.2 g/ml for patients without local recurrence.
In (Ashamalla et al., 2014) , SUVMax was correlated with OS in univariate analysis, but not in multivariate analysis. Only 28 patients were included in this study, which may explain this negative result.
The Metabolic Tumor Volume (MTV), defined as the volume of FDG activity in a tumor assessed by automated volume of interest delineation, and Total Lesion Glycolysis (TLG), defined as MTV x SUVmean, may be more representative of the tumor heterogeneity. The predictive value of MTV was evaluated in 26 studies, with 21 of them also evaluating SUVMax (for a total of 1464 patients). All these studies showed that MTV/TLG were predictive for clinical outcome, with a higher predictive value than SUVmax. In (Chang et al., 2012) , 108 patients with nasopharyngeal cancer treated with RT-CT were prospectively included to assess the predictive value of SUVMax, MTV and TLG for DFS and OS. Only Epstein-Barr virus DNA load and TLG of the tumor were significantly correlated with DFS and OS. In particular, patients presenting a TLG value < 65 g showed a 3-year DFS of 79.9% versus 37.4% for other patients (p<0.001), with a hazard ratio of 3.54 (p=0.006) for DFS and of 4.91 (p=0.045) for OS.
In two studies, MTV was found to have a higher predictive value than TNM staging (Kao et al., 2012; Romesser et al., 2014) . (Romesser et al., 2014) reported data of 100 oropharyngeal cancer, treated with RT-CT (median follow-up: 49 months). MTV at a cutoff of 9.7 mL was correlated with DFS (80.3% vs 56.7%, p=0.015) and OS (84.1% vs 57.8% p=0.008). In multivariate analysis, only MTV was significant while GTV, T stage and N stage did not. Noteworthy, the reproducibility of the MTV and/or TLG may be limited by the initial definition of these parameters, which is based on a threshold of SUV, absolute (all pixels with SUV value > x) or relative (all pixels with SUV value > xx % of SUVMax). The choice of the threshold for either method may affect the absolute value of the MTV. Six studies compared the predictive value of MTV and/or TLG computed with different thresholds (Cheng et al., 2015; Kao et al., 2012; Lin et al., 2015; Schinagl et al., 2011; Yabuki et al., 2015) . In the study by (Schinagl et al., 2011) , 4 thresholds (2.5, 40%, 50% and adaptive threshold based on liver uptake) were compared for 77 patients treated with RT +/-CT. MTV 40% was the strongest predictor of DFS and OS. However, even if the predictive value of the other thresholds was slightly lower, they were also correlated with OS and DFS. Same results were reported by the others studies.
Based on these results, the use of different thresholds within a reasonable range (between 2 and 3 for an absolute threshold; and between 40 -50 % for a relative threshold) seems to have no major impact on the predictive value of MTV.
Texture and shape analysis
Two different approaches have been used to evaluate tumor heterogeneity, one morphological at macroscopic level (shape of the metabolic area) and the other at pixel level (texture analysis). (Apostolova et al., 2014 ) used a new parameter to characterize the deviation of the tumor's shape from sphere symmetry (asphericity). The initial assumption of the authors was that "aggressive" tumors are expected to show more irregular shapes, due to necrosis, angiogenesis and extravascular extracellular matrix. In a first study, including patients treated with surgery, radiotherapy or chemotherapy alone, asphericity was correlated with OS and PFS. Based on these results, the authors tried to confirm the predictive value of asphericity in a following study (Hofheinz et al., 2015) . Thirty-three patients, with LAHNC treated with RT-CT were included. Using the same cutoff of 20.4 found in (Apostolova et al., 2014) , asphericity was correlated with PFS (HR 2.96, p= 0.015) and OS (HR 5.9, p=0.001).
Two studies evaluated the prognostic value of texture analysis in LAHNC. In the first study (Cheng et al., 2013) , including 70 oropharyngeal cancers, TLG and texture uniformity were correlated with OS (HR 5.85 and 0.46 respectively). A 3-point risk scale for DFS and OS was proposed, according to the presence of a uniformity ≤ 0.138 and a TLG > 122.9 g. One point was given for each factor. Clinical outcome (DFS or OS) was significantly different in the 3 risk groups. These findings were confirmed in an independent series of 88 oropharyngeal cancer patients (Cheng et al., 2015) .
Predictive value of quantitative PET parameters during chemoradiotherapy
Early changes in tumor metabolism during radiochemotherapy may be assessed by PET/CT and may be used to tailor treatment. The aims of this adaptive strategy to the treatment' response are to decrease the adverse effect and/or to intensify the treatment, with the final goal to improve the outcome.
Seven studies (374 patients) evaluated the predictive value of PET performed during RT +/-CT (Brun et al., 2002; Castaldi et al., 2012; Chen et al., 2014; Farrag et al., 2010; Hentschel et al., 2011; Min et al., 2016; Min et al., 2015) . All but one of them found a correlation between PET parameters RT +/-CT and clinical outcome. In a study by Min et al., 100 patients received a PET before and 3 weeks after the beginning of treatment (Min et al., 2016) . The authors showed that pre-treatment SUVMax and mid-treatment TLG were correlated with 2-year DFS in multivariate analysis (83% vs 71.4%, p=0.0019 and 88.4% vs 77.2%, p=0.012, respectively).
Moreover, patients presenting pretreatment TLG < 91 g and a mid-treatment TLG < 9.4 g presented a better 2-year DFS (88.1% vs 61.1%, p=0.001) and 2-year OS (90% vs 67%, p=0.012).
Other parameter,such as SUVMax and MTV were also correlated to DFS and OS, but TLG was the most predictive one. In (Castaldi et al., 2012) , which included 24 patients, no predictive value of PET during treatment was shown. However, the decrease of SUVmax between PET at diagnosis and during treatment was highly correlated with 2-year DFS (100% in case of complete response vs 74% in case of partial response, defined as a reduction of 25% in tumor 18FDG SUV (Young et al., 1999) ).
The optimal time to perform PET during treatment is still unclear. Most of the studies performed the PET before the third week to allow time for adapting therapy. A prospective multicentric study (TEMPORAL) (NCT02469922) is undergoing to assess the predictive value of PET at the 2nd and 4th week of chemoradiotherapy. One hundred twenty-three patients are expected to be included.
Predictive value of 18FDG PET after treatment
After treatment with radiotherapy, PET/CT may be used to identify good responders and avoid useless neck dissection. Twelve studies performed a quantitative or semi quantitative analysis from PET after treatment. All these studies evaluated the SUVMax. A high SUVMax in post treatment was correlated with a poor outcome in 6 studies (Horiuchi et al., 2008; Hoshikawa et al., 2011; Ito et al., 2014; Kim et al., 2016; Kitagawa et al., 2003; Moeller et al., 2010) . In (Moeller et al., 2010) , 98 patients underwent a PET before and 8 weeks after RT +/-CT. The authors found that a post-treatment SUVMax < 6 g/ml and the variation of SUVMax (in %) between the pre-and post-irradiation PET/CT were predictive for DFS. In (Kim et al., 2016) , a PET was performed 3 months after RT-CT. Seventy-eight patients were analyzed. Three-year OS was 87.7% in patients with SUVMax <4.4 g/ml versus 56.9% (p=0.002).
A comparison between visual analysis and quantitative parameters was performed by (Hoshikawa et al., 2009) . Thirty-five patients underwent PET before and 5 weeks after RT-CT.
Patients with a post-treatment SUVMax value > 3 g/ml and decreasing less than 60% compared to the pre-treatment situation presented a higher risk of recurrence (odds ratio = 61.5, p<0.0001). The overall accuracy for quantitative analysis was 89.9% vs 60.9% for the visual analysis.
Discussion and conclusion
This overview of the available literature shows that MTV and TLG are well correlated with clinical outcome (Local control, Disease Free Survival and overall survical). Most of the available data deal with the intensity of the metabolism, calculated from the SUV, a quantitative parameter used to normalize the uptake of 18 F-FDG. In practice, SUV is defined as a ratio of tissue radioactivity concentration and the injected dose adjusted by body weight (SUVbw with BW for body weight). Intensity of the metabolism can be analyzed using histogram-based method, which represents the voxel value frequency distribution. This method includes in particular the four histogram moments, i.e., the mean (corresponding to SUVMean), the maximum (corresponding to SUVMax), the median, the skewness (asymmetry of the histogram) and kurtosis (degree of peakedness of a distribution). However, it did not take into account the spatial relationship between voxel values (Fig. 1) .
The maximum SUV (SUVMax) corresponds to the maximal pixel value in the tumor. Thanks to its ease of use, it is one of the most used parameters in the clinical practice. However, this value is highly dependent from noise, duration and parameters of acquisition, and so is considered to be poorly reproducible (Boellaard et al., 2004; Nahmias and Wahl, 2008; Nakamoto et al., 2002) . This point may explain the wide range of cut-off value for SUVmax reported in the available studies (from 3.7 to 9 g/ml), limiting the generalization of the use of SUVmax for the whole population. Peak SUV (SUVPeak), defined as the average SUV within a small region of interest (1.2 cm of diameter) around the SUVMax, is a more robust alternative to SUVMax. However, SUVPeak may not be representative of nonhomogeneous overall tumor uptake, and the ideal size of the ROI is still unclear (Lee et al., 2007) .
Others volumetric parameters like the MTV, the mean SUV within the tumor volume or the TLG are used to represent the heterogeneity of the tumor uptake. The predictive value for clinical outcome of these parameters seems to be higher than SUVMax. However, uptake in PET may be due to inflammatory or infectious reaction. Furthermore, the physiological uptake surrounding organs can also be a source of loss of specificity in the analysis of the signal. A major difficulty in the analysis of PET is to differentiate the tumor signal from the non-tumor signal. PET imaging suffers from a low contrast and spatial resolution, with a high noise background and partial effect volume. Tumor delineation may change depending on the chosen segmentation method. One of the most used automatic method is to use a threshold, between 2 and 3 (absolute value) or 40-50% (relative value of SUVmax).
One important issue concerning the predictive value of MTV is the lack of external validation.
Most of the studies were monocentric, using the same PET/CT for all patients. Only two studies performed a validation on an independent dataset (Hofheinz et al., 2015; Tang et al., 2012) . The first study (La et al., 2009 ) included 85 patients and showed that an increase of MTV of 17 cm 3 (from the 25th to 75th percentile) was significantly correlated with an increased risk of death (HR 2.1). The authors validated their results on a dataset of 83 patients treated in the same institution after the original dataset (Tang et al., 2012) . Based on (Apostolova et al., 2014) , (Hofheinz et al., 2015) used a cutoff of TLG of 58.7 ml. They showed a correlation of TLG only with better DFS (HR 3.01, p=0.048) but not with better OS (HR 2.02, p=0.22). After adjusting the cutoff at a value of 141 ml, TLG was also correlated with OS (HR 3.32, p=0.016). Such methodologies and findings highlight the difficulty in identifying a cutoff which may be tested on external dataset of patients. The use of international guidelines, like the European Association of Nuclear Medecine guidelines for tumor imaging (Boellaard et al., 2015) , by harmonizing quantitative FDG PET/CT imaging procedures in multicentre studies and quantitative interpretation criteria, may increases the reproducibility of PET studies.
The spatial relationships between the voxel values within the tumor may be assessed by texture analyses. Texture analyses aim to characterize the internal metabolism morphology of the tumors. From a technical point of view, they characterize the transitions between voxel values. Several approaches exist and they all rely on a quantification of spatial scales organization and directions in images. Most approaches are computing the latter in two dimensions on a slice basis. The most widely used method is the Gray Level Co-occurrence Matrix and consists in calculating matrices counting the co-occurrences of two voxels values separated from a set of fixed distances and along set of fixed directions. Several statistics can be computed on these matrices to quantify textural properties (e.g., correlation, contrast, energy). Another popular approach is to apply image filters with various scales and directional properties to continuously quantify transitions between image voxels. One popular example is the isotropic Mexican hat filter (also called Laplacian of Gaussian filter) . A comprehensive review of methods for 3-D texture analysis is available in (Depeursinge et al., 2014) . This kind of analysis seems promising, but its use should still be considered experimental and limited to clinical studies.
Unresolved questions and controversies 1. Reproducibility of PET parameters between different machines and/or centre 2. Which methods (Manually, relative, absolute or adaptive segmentation) and which threshold to compute MTV ? 3. When should perform PET during radiotherapy ? 4. Which methods for texture and shape analysis ? 
SUV Peak
Average SUV within a small, fixed-size region of interest (ROIpeak) of 1.2 cm diameter, centered on a high-uptake part of the tumor
Metabolic Tumor Volume (MTV)
Sum of the volume of voxels with SUV exceeding a certain threshold value in a tumor
SUV Mean
Average SUV in the ROI (defined by applying a threshold or by visual assessment)
Total Lesion Glycolysis (TLG)
TLG is obtained by multiplying MTV and the mean SUV of the MTV 
